ScandiDos launches Delta4 Insight which is immediately available to sell to customers in Europe and parts of Asia.
Delta4 Insight provides radiotherapy clinics with an independent QA solution that verifies the accuracy and quality of their treatment plans. Featuring a state-of -the art Monte Carlo dose engine, enabling exceptional calculation accuracy, giving the clinic full confidence that the planned treatments fulfil the prescription for each specific patient. Delta4 Insight extends the Delta4 family of products into a full end-to end verification solution.
Delta4 Insight - Golden standard secondary dose calculation
Delta4 Insight is an independent secondary 3D dose calculation software that utilizes a Monte Carlo engine to verify the calculations of a clinic’s Treatment Planning System (TPS). It provides the user with an independent verification of the dose calculation algorithm and verifies that the calculations the TPS makes are accurate.
Delta4 Insight completes the ScandiDos patient QA product portfolio which now covers patient QA from prescription to final fraction. Not only can Delta4 users expect to increase the workflow efficiency but, most importantly, they can also carry out their work with full confidence that throughout the whole treatment process the dose delivered to patients are safe.
”Our ambition when developing Delta4 Insight was to extend our Delta4 family of products into a full end-to-end verification solution where the customer can be confident that Delta4 provides the true values and not just the deviations”, says Görgen Nilsson, CTO and founder.
Delta4 Insight will initially be available in most of Europe and key markets in Asia, but further markets will be addressed based on regulatory approvals. Primary target groups are current Delta4 Phantom+ customers, today over 800 clinics, and radiotherapy clinics buying the Delta4 Phantom+.
” I am very pleased that we are now bringing Delta4 Insight to market. Together with ScandiDos’ existing products Delta4 Phantom+ and Delta4 Discover, Delta4 Insight will offer independent and complete verifications of all treatment steps from prescription to final treatment fraction”, says Gustaf Piehl, President & CEO.